News

The EPINEPHRINE INJECTION, USP, 1:1000 (0.3mg Pre-filled single dose syringe) is designed for the emergency treatment of allergic reactions (Type I) including anaphylaxis. The company’s PFS provides a

The global agreement will initially focus on Advaxis’s lead immunotherapy for cervical cancer, ADXS-HPV. As part of the deal, inVentiv will provide Advaxis with full CRO services to

The agreement will allow the company to assess its modified recombinant human albumin (rAlbumin) Veltis technology, to evaluate the dosing and performance of a novel subunit antigen vaccine

The company is currently carrying out in-vitro testing on these candidates using a robust screening process developed during testing of more advanced products that incorporate the DETERx technology

The company has partnered with Andrus for the distribution of Binosto in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan. Through another partnership,

The collaboration target and lead inhibitors were discovered through Array’s Kinase-Directed Phenotypic Screening Platform, which relies on the company’s deep experience in kinase inhibitor chemistry and phenotypic screening

Natesto, formerly CompleoTRT, is self-administered via a nasal applicator thereby reducing the risk of secondary exposure to testosterone of women or children. Clinical Research of South Florida (CRSA)

The company also received a second patent for ZORVOLEX (diclofenac) capsules covering its manufacturing method. ZORVOLEX and TIVORBEX were approved in October 2013 and February 2014, respectively, by

Euprotec is a recognised leader in anti-infective drug discovery services. With a comprehensive portfolio of assays and disease models, underpinned by internationally recognised expertise, the company supports each